LATEST NEWS

A new radio-enhancer, PEP503 (NBTXR3), in combination with concurrent chemoradiation in locally advanced or unresectable rectal cancer: The dose-finding part of a phase I/II trial

For inquiries about our technology, collaborations, clinical trials, or other topics, we encourage you to get in touch with our team.